-
公开(公告)号：US10226525B2
公开(公告)日：2019-03-12
申请号：US15144884
申请日：2016-05-03
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20180022783A1
公开(公告)日：2018-01-25
申请号：US15728610
申请日：2017-10-10
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: C07K14/22 , A61K39/39 , A61K39/295 , A61K39/00 , A61K39/12 , A61K39/095 , C12N7/00 , A61K39/13
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20160347797A1
公开(公告)日：2016-12-01
申请号：US15237005
申请日：2016-08-15
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: C07K14/22 , A61K39/095
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 68. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal
Abstract translation: 一方面，本发明涉及分离的多肽，其包含与SEQ ID NO：68具有至少95％同一性的氨基酸序列。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化的ORF2086多肽和来自脑膜炎球菌的至少一种共轭荚膜糖
-
34.发明申请Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof 有权包含共轭荚膜糖抗原的免疫原性组合物及其用途公开(公告)号：US20150202309A1
公开(公告)日：2015-07-23
申请号：US14597488
申请日：2015-01-15
Applicant: PFIZER INC.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K47/4833 , A61K39/092 , A61K47/646 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。
-
公开(公告)号：US20130243807A1
公开(公告)日：2013-09-19
申请号：US13787594
申请日：2013-03-06
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: A61K39/095 , C07K14/22
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。
-
Patent Agency Ranking
36.发明授权公开(公告)号：US11872274B2
公开(公告)日：2024-01-16
申请号：US17194224
申请日：2021-03-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-Ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/30
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号：US20230190907A1
公开(公告)日：2023-06-22
申请号：US17812777
申请日：2022-07-15
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
CPC classification number: A61K39/092 , A61K39/39 , A61K2039/55505
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
公开(公告)号：US20230173051A1
公开(公告)日：2023-06-08
申请号：US17917624
申请日：2021-04-09
Applicant: Valneva Austria GmbH , Pfizer Inc.
Inventor： Nicole Bézay , Romana Hochreiter , Urban Lundberb , Steven Russell Bailey , Annaliesa Sybil Anderson , Kathrin Ute Jansen , Daniel Alfred Scott
CPC classification number: A61K39/0225 , A61P37/04 , A61K2039/55505
Abstract: The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
-
公开(公告)号：US11413344B2
公开(公告)日：2022-08-16
申请号：US16478265
申请日：2018-01-05
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
公开(公告)号：US20220118072A1
公开(公告)日：2022-04-21
申请号：US17428487
申请日：2020-02-07
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Paul Liberator , Thomas Richard Jones , Kathrin Ute Jansen , John Lance Perez , Shannon Lea Harris
IPC: A61K39/095 , A61K47/26 , A61K47/22 , A61K47/02
Abstract: In one aspect, the invention relates to use of a composition including a first polypeptide and a second polypeptide, wherein the composition elicits an immune response against Neisseria meningitis serogroup B strains expressing, for example, variants A02, A28, A42, A63, A76, B05, B07, B08, B13, B52 and B107.
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.023 seconds)
